Skip to main content
. 2022 Jan 13;14(2):400. doi: 10.3390/cancers14020400

Figure 3.

Figure 3

bDFS and clinical RFS rates. (a) bDFS with and without hyperthermia treatment. (b) bDFS among patients administered a thermal dose of CEM43T90 > 7 min, CEM43T90 ≤ 7 min, or no hyperthermia treatment. (c) Comparison of clinical RFS between the groups with and without hyperthermia treatment. (d) Comparison of clinical RFS among the patients with thermal dose CEM43T90 > 7 min, CEM43T90 ≤ 7 min, and no hyperthermia treatment.